Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

Lac-Hydrin

&times

Overview

What is Lac-Hydrin?

Lac-Hydrin specially formulates 12% lactic acid, neutralized with ammonium hydroxide, as ammonium lactate to provide a lotion pH of 4.4-5.5. Lac-Hydrin (ammonium lactate) Lotion 12% also contains cetyl alcohol, fragrance, glycerin, glyceryl stearate, laureth-4, light mineral oil, magnesium aluminum silicate, methylcellulose, methyl- and propyl parabens, PEG-100 stearate, polyoxyl 40 stearate, propylene glycol and water. Lactic acid is a racemic mixture of 2-hydroxypropanoic acid and has the following structural formula:



What does Lac-Hydrin look like?



What are the available doses of Lac-Hydrin?

Sorry No records found.

What should I talk to my health care provider before I take Lac-Hydrin?

Sorry No records found

How should I use Lac-Hydrin?

Sorry No records found


What interacts with Lac-Hydrin?

Lac-Hydrin Lotion is contraindicated in those patients with a history of hypersensitivity to any of the label ingredients.



What are the warnings of Lac-Hydrin?

Sorry No Records found


What are the precautions of Lac-Hydrin?

General

For external use only. Stinging or burning may occur when applied to skin with fissures, erosions, or that is otherwise abraded (for example, after shaving the legs). Caution is advised when used on the face because of the potential for irritation. The potential for post-inflammatory hypo- or hyperpigmentation has not been studied.

Information For Patients









          Patients using Lac-Hydrin (ammonium lactate) Lotion, 12% should receive the following information and instructions:

          Carcinogenesis, Mutagenesis, Impairment of Fertility

          The topical treatment of CD-1 mice with 12%, 21% or 30% ammonium lactate formulations for two years did not produce a significant increase in dermal or systemic tumors in the absence of increased exposure to ultraviolet radiation. The maximum systemic exposure of the mice in this study was 0.7 times the maximum possible systemic exposure in humans. However, a long-term photocarcinogenicity study in hairless albino mice suggested that topically applied 12% ammonium lactate formulations enhanced the rate of ultraviolet light-induced skin tumor formation.

          The mutagenic potential of ammonium lactate formulations was evaluated in the Ames assay and in the mouse micronucleus assay, both of which were negative.

          In dermal Segment I and III studies with ammonium lactate formulations there were no effects observed in fertility or pre- or post-natal development parameters in rats at dose levels of 300 mg/kg/day (1800 mg/m/day), approximately 0.4 times the human topical dose.

          Pregnancy

          Animal reproduction studies have been performed in rats and rabbits at doses up to 0.7 and 1.5 times the human dose, respectively (600 mg/kg/day, corresponding to 3600 mg/m/day in the rat and 7200 mg/m/day in the rabbit) and have revealed no evidence of impaired fertility or harm to the fetus due to ammonium lactate formulations. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, Lac-Hydrin Lotion should be used during pregnancy only if clearly needed.

          Nursing Mothers

          Although lactic acid is a normal constituent of blood and tissues, it is not known to what extent this drug affects normal lactic acid levels in human milk. Because many drugs are excreted in human milk, caution should be exercised when Lac-Hydrin is administered to a nursing woman.

          Pediatric Use

          Safety and effectiveness of Lac-Hydrin have been demonstrated in infants and children. No unusual toxic effects were reported.

          Geriatric Use

          Clinical studies of Lac-Hydrin (ammonium lactate) Lotion, 12% did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between elderly and younger patients. In general, dose selection for an elderly patient should be cautious.


          What are the side effects of Lac-Hydrin?

          The most frequent adverse experiences in patients with xeroxis are transient stinging (1 in 30 patients), burning (1 in 30 patients), erythema (1 in 50 patients) and peeling (1 in 60 patients). Other adverse reactions which occur less frequently are irritation, eczema, petechiae, dryness and hyperpigmentation.

          Due to more severe initial skin conditions associated with ichthyosis, there was a higher incidence of transient stinging, burning and erythema (each occurring in 1 in 10 patients).


          What should I look out for while using Lac-Hydrin?

          Lac-Hydrin Lotion is contraindicated in those patients with a history of hypersensitivity to any of the label ingredients.

          Sun exposure to areas of the skin treated with Lac-Hydrin (ammonium lactate) Lotion, 12% should be minimized or avoided (see ). The use of Lac-Hydrin Lotion should be discontinued if any hypersensitivity is observed.


          What might happen if I take too much Lac-Hydrin?

          Sorry No Records found


          How should I store and handle Lac-Hydrin?

          Store the kit at 2°-8°C (36°-46°F) and protect from light.ArrayStore the kit at 2°-8°C (36°-46°F) and protect from light.ArrayLac-Hydrin (ammonium lactate) Lotion, 12% is available in a 225g (NDC # 0072-5712-08) plastic bottle and 400g (NDC # 0072-5712-14) plastic bottle.Store at controlled room temperature 15° C - 30° C (59° F - 86° F).Manufactured for:Bristol-Myers Squibb CoPrinceton, NJ 08543 USABy: Contract Pharmaceuticals Limited NiagaraBuffalo, NY 14213 USARevised January 2008Lac-Hydrin (ammonium lactate) Lotion, 12% is available in a 225g (NDC # 0072-5712-08) plastic bottle and 400g (NDC # 0072-5712-14) plastic bottle.Store at controlled room temperature 15° C - 30° C (59° F - 86° F).Manufactured for:Bristol-Myers Squibb CoPrinceton, NJ 08543 USABy: Contract Pharmaceuticals Limited NiagaraBuffalo, NY 14213 USARevised January 2008Lac-Hydrin (ammonium lactate) Lotion, 12% is available in a 225g (NDC # 0072-5712-08) plastic bottle and 400g (NDC # 0072-5712-14) plastic bottle.Store at controlled room temperature 15° C - 30° C (59° F - 86° F).Manufactured for:Bristol-Myers Squibb CoPrinceton, NJ 08543 USABy: Contract Pharmaceuticals Limited NiagaraBuffalo, NY 14213 USARevised January 2008Lac-Hydrin (ammonium lactate) Lotion, 12% is available in a 225g (NDC # 0072-5712-08) plastic bottle and 400g (NDC # 0072-5712-14) plastic bottle.Store at controlled room temperature 15° C - 30° C (59° F - 86° F).Manufactured for:Bristol-Myers Squibb CoPrinceton, NJ 08543 USABy: Contract Pharmaceuticals Limited NiagaraBuffalo, NY 14213 USARevised January 2008Lac-Hydrin (ammonium lactate) Lotion, 12% is available in a 225g (NDC # 0072-5712-08) plastic bottle and 400g (NDC # 0072-5712-14) plastic bottle.Store at controlled room temperature 15° C - 30° C (59° F - 86° F).Manufactured for:Bristol-Myers Squibb CoPrinceton, NJ 08543 USABy: Contract Pharmaceuticals Limited NiagaraBuffalo, NY 14213 USARevised January 2008Lac-Hydrin (ammonium lactate) Lotion, 12% is available in a 225g (NDC # 0072-5712-08) plastic bottle and 400g (NDC # 0072-5712-14) plastic bottle.Store at controlled room temperature 15° C - 30° C (59° F - 86° F).Manufactured for:Bristol-Myers Squibb CoPrinceton, NJ 08543 USABy: Contract Pharmaceuticals Limited NiagaraBuffalo, NY 14213 USARevised January 2008Lac-Hydrin (ammonium lactate) Lotion, 12% is available in a 225g (NDC # 0072-5712-08) plastic bottle and 400g (NDC # 0072-5712-14) plastic bottle.Store at controlled room temperature 15° C - 30° C (59° F - 86° F).Manufactured for:Bristol-Myers Squibb CoPrinceton, NJ 08543 USABy: Contract Pharmaceuticals Limited NiagaraBuffalo, NY 14213 USARevised January 2008Lac-Hydrin (ammonium lactate) Lotion, 12% is available in a 225g (NDC # 0072-5712-08) plastic bottle and 400g (NDC # 0072-5712-14) plastic bottle.Store at controlled room temperature 15° C - 30° C (59° F - 86° F).Manufactured for:Bristol-Myers Squibb CoPrinceton, NJ 08543 USABy: Contract Pharmaceuticals Limited NiagaraBuffalo, NY 14213 USARevised January 2008


          &times

          Clinical Information

          Chemical Structure

          No Image found
          Clinical Pharmacology

          Lactic acid is an alpha-hydroxy acid. It is a normal constituent of tissues and blood. The alpha-hydroxy acids (and their salts) may act as humectants when applied to the skin. This property may influence hydration of the stratum corneum. In addition, lactic acid, when applied to the skin, may act to decrease corneocyte cohesion. The mechanism(s) by which this is accomplished is not yet known.

          An study of percutaneous absorption of Lac-Hydrin Lotion using human cadaver skin indicates that approximately 5.8% of the material was absorbed after 68 hours.

          Non-Clinical Toxicology
          Lac-Hydrin Lotion is contraindicated in those patients with a history of hypersensitivity to any of the label ingredients.

          Sun exposure to areas of the skin treated with Lac-Hydrin (ammonium lactate) Lotion, 12% should be minimized or avoided (see ). The use of Lac-Hydrin Lotion should be discontinued if any hypersensitivity is observed.

          For external use only. Stinging or burning may occur when applied to skin with fissures, erosions, or that is otherwise abraded (for example, after shaving the legs). Caution is advised when used on the face because of the potential for irritation. The potential for post-inflammatory hypo- or hyperpigmentation has not been studied.

          The most frequent adverse experiences in patients with xeroxis are transient stinging (1 in 30 patients), burning (1 in 30 patients), erythema (1 in 50 patients) and peeling (1 in 60 patients). Other adverse reactions which occur less frequently are irritation, eczema, petechiae, dryness and hyperpigmentation.

          Due to more severe initial skin conditions associated with ichthyosis, there was a higher incidence of transient stinging, burning and erythema (each occurring in 1 in 10 patients).

          &times

          Reference

          This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
          "https://dailymed.nlm.nih.gov/dailymed/"

          While we update our database periodically, we cannot guarantee it is always updated to the latest version.

          &times

          Review

          Rate this treatment and share your opinion


          Helpful tips to write a good review:

          1. Only share your first hand experience as a consumer or a care giver.
          2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
          3. Fill in the optional information to help other users benefit from your review.

          Reason for Taking This Treatment

          (required)

          Click the stars to rate this treatment

          This medication has worked for me.




          This medication has been easy for me to use.




          Overall, I have been satisfied with my experience.




          Write a brief description of your experience with this treatment:

          2000 characters remaining

          Optional Information

          Help others benefit from your review by filling in the information below.
          I am a:
          Gender:
          &times

          Professional

          Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
          &times

          Tips

          Tips

          &times

          Interactions

          Interactions

          A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).